Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate
Liver International · 2025
DOI: 10.1111/liv.70357 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Liver International, 2025. Verfasst von Jiwon Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Tenofovir. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background and Aims In phase 3 trials, tenofovir alafenamide (TAF) showed antiviral efficacy comparable to that of tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB), with an improved safety profile. This study aimed to compare the clinical efficacy of TAF and TDF in terms of the risk of hepatocellular carcinoma (HCC).
Methods
We conducted a nationwide historical population cohort study on treatment‐naïve adult patients with CHB receiving TAF ( n = 29 309) or TDF ( n = 58 046) as first‐line therapy from 2017 to 2022 using data from the Korean National Health Insurance Service database. Cumulative HCC incidence and associated risk factors were estimated using competing risk factors. Propensity score (PS)‐matched analysis was used to minimise the confounding effects.
Results
A total of 54 185 patients were included in the study, with 20 994 in the TAF group and 33 191 in the TDF group. The annual incidence of HCC was significantly lower in the TAF group (7.5/1000 patient‐years [PYs]) than in the TDF group (10.3/1000 PYs; subdistribution hazard ratio [SHR], 0.74; p < 0.001). After PS matching, TAF continued to exhibit a protective effect against HCC (7.5/1000 PYs vs. 9.9/1000 PYs; p < 0.001). Multivariable analysis with Fine–Gray proportional subdistribution hazards model identified TAF as significantly associated with a reduced HCC incidence (SHR: 0.76; p < 0.001). Subgroup analysis confirmed the hepatoprotective effect of TAF against HCC even in patients with cirrhosis (SHR: 0.78; p = 0.003).
Conclusion
This study showed that TAF had a hepatoprotective effect against HCC in patients with CHB, providing valuable guidance for clinicians in selecting the appropriate initial treatment for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, the Catholic University of Korea, Seoul, Korea.
- Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
ORCID-Profile: Jiwon Yang, Jihye Lim
Zitieren
APA
Yang, J., Lim, J., Kim, Y. J., Kim, H. J., & Choi, J. (2025). Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate. Liver International. https://doi.org/10.1111/liv.70357
Vancouver
Yang J, Lim J, Kim YJ, Kim HJ, Choi J. Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate. Liver International. 2025. doi:10.1111/liv.70357
BibTeX
@article{Yang2025,
author = {Yang, Jiwon and Lim, Jihye and Kim, Ye-Jee and Kim, Hwa Jung and Choi, Jonggi},
title = {Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70357}
}
EUVIMED